2021 Fiscal Year Final Research Report
Investigating the anti-inflammatory mechanism of 5-ASA and exploring the new therapeutic strategy for IBD by the comprehensive analysis for the gut microbiome
| Project/Area Number |
19K08380
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Kyorin University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 炎症性腸疾患 / 5-アミノサリチル酸 / 腸管微生物叢 / 抗炎症作用 |
|---|
| Outline of Final Research Achievements |
5-aminosalicylic acid (5-ASA) is widely used as a therapeutic agent for inflammatory bowel disease (IBD). However, the anti-inflammatory mechanism of 5-ASA remains unclear. The present study analyzed the gut bacterial compositions using 16S rRNA amplicon sequencing and assessed the host intestinal mucosal immune system. This study showed that 5-ASA alters the gut microbiome affecting intestinal immunity. These results suggested that the impact of 5-ASA on the gut microbiome is one of the anti-inflammatory mechanisms of 5-ASA.
|
| Free Research Field |
消化器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
5-アミノサリチル酸製剤（5-ASA）は、比較的安価であり、その忍容性と有効性が長期的に実証されている炎症性腸疾患（IBD）治療薬である。IBD患者数は増加傾向にあり、5-ASA製剤の抗炎症機序を明らかにすることは、医学的のみならず医療経済に貢献する新たな治療選択肢の開発につながる可能性がある。本研究成果は、5-ASAの腸管微生物叢を介する作用機序の解明、IBD治療に用いるプロバイオティクスの探索につながるものと考えられる。
|
